Stock Price Quote

MANGALAM DRUGS AND ORGANICS LTD.

NSE : MANGALAMBSE : 532637ISIN CODE : INE584F01014Industry : Pharmaceuticals & DrugsHouse : Private
BSE99.700.21 (+0.21 %)
PREV CLOSE ( ) 99.49
OPEN PRICE ( ) 98.00
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 2918
TODAY'S LOW / HIGH ( )98.00 101.00
52 WK LOW / HIGH ( )85.16 132.4
NSE99.950.8 (+0.81 %)
PREV CLOSE( ) 99.15
OPEN PRICE ( ) 99.70
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 18437
TODAY'S LOW / HIGH( ) 98.45 100.60
52 WK LOW / HIGH ( )90.8 132.45
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 1972
Management Info
Govardhan M Dhoot - Chairman Govardhan M Dhoot - Managing Director
Registered Office

Address ‘3” Floor,239, Rupam Building,P. D. Mello Road, Near G P O,
Mumbai,
Maharashtra-400001

Phone 022-22616200 / 6300

Email contactus@mangalamdrugs.com

Website www.mangalamdrugs.com

Registrars Details
Link Intime India Pvt Ltd.
C 101, 247 Park,LBS Marg,Vikhroli (West),Mumbai
Listing : BSE, NSE

NEWS

16Mar Mangalam Drugs & Organics informs abou
Mangalam Drugs & Organics has informed that the Board of Directors o..
11Mar Merger
Inter alia to consider and approve: The proposal of Scheme of Merger
02Mar Mangalam Drugs & Organics informs abou
Mangalam Drugs & Organics has informed that the Exchange has receive..
06Feb Mangalam Drugs & Organics informs abou
Mangalam Drugs & Organics has informed that the meeting of the Board..
28Nov Mangalam Drugs & Organics informs abou
Mangalam Drugs & Organics has informed that it enclosed Disclosure u..

Financials

in Millions
QTR Dec 23 ANNUAL 23
Net Profit4.9999999999999712.7
Gross Profit 0.439999999999969 22.14
Operating Profit 69.78259.54
Net Sales 973.363722.53

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Bharat Parenterals (BSE)
peergroup  1455.20 (10.00%)
M.Cap ( in Cr)846.88
Solara Active Pharma (BSE)
peergroup  551.45 (16.32%)
M.Cap ( in Cr)1985.01
Abbott India (BSE)
peergroup  26131.85 (0.29%)
M.Cap ( in Cr)55528.36
Windlas Biotech (BSE)
peergroup  555.05 (6.97%)
M.Cap ( in Cr)1154.42
Concord Biotech (BSE)
peergroup  1595.25 (1.05%)
M.Cap ( in Cr)16688.90

Shareholding Pattern

PROMOTERS 50.32%
NON-INSTITUTION 49.58%
FI/BANKS/INSURANCE 0%
MUTUAL FUNDS/UTI 0%
GOVERNMENT 0%
FII 0%

About Mangalam Drugs And Organics Ltd.

Mangalam Drugs And Organics Ltd. was incorporated in the year 1972. Its today's share price is 99.7. Its current market capitalisation stands at Rs 157.81 Cr. In the latest quarter, company has reported Gross Sales of Rs. 3722.53 Cr and Total Income of Rs.3726.89 Cr. The company's management includes Jayant Barde, Rakesh K Milwani, Praveen Saxena, Nidhi Mundada, Rukmesh Dhandhania, Brijmohan M Dhoot, Govardhan M Dhoot, Govardhan M Dhoot.

It is listed on the BSE with a BSE Code of 532637 , NSE with an NSE Symbol of MANGALAM and ISIN of INE584F01014. It's Registered office is at ‘3” Floor,239, Rupam Building,P. D. Mello Road, Near G P OMumbai-400001, Maharashtra. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are Batliboi & Purohit, Milwani Associates, VS Somani & Co

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.